Studies of cardiovascular outcomes have revealed the benefits of the cardiovascular system in patients with T2DM treated with long-acting GLP-1RAs
Because Wegovy (when approved at its highest dose) produces rapid weight loss and sharper metabolic shifts, this could drive the stronger association by predisposing to optic nerve hypoperfusion through intravascular volume contraction, hypotension with nocturnal dips and autonomic instability. For ophthalmologists, the findings highlight a potential safety signal that warrants further investigation but should be interpreted cautiously
This addition is particularly significant for researchers interested in the thermogenic properties of glucagon and how it might influence hepatic lipid metabolism alongside insulinotropic pathways
2024;doi:10.1056/NEJMoa2403347) demonstrated that addition of semaglutide (Ozempic/Wegovy, Novo Nordisk) to an SGLT2 inhibitor showed no renal protective effect (HR = 1.07, 95% CI 0.69-1.67), although the number of subjects receiving an SGLT2 (16%) in this study was relatively small
This map provides an overview of Medicaid CGM coverage in the US but keep in mind that coverage varies by state and many factors contribute to your eligibility for a CGM
